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Abstract
Although phase I to III trials represent the standard for introducing
new drugs to clinical therapy, there has been increasing demand
for translational research in oncology over the past decade. Thus,
for most novel therapies such as ‘targeted agents’, a critical aspect
for drug development in oncology has been to select the right
patients for therapy. Translational research plays a pivotal role, not
only in phase II trials but also in phase I and III and even in phase IV
trials. The importance of distinguishing between our translational
‘aims’ in phase II and phase III trials is emphasized. Although
translational research in phase III trials aims to identify optimal
markers for clinical use, phase II studies may represent an optimal
setting to explore tumour biology and the mechanisms of drug
resistance in depth.
Introduction
The roles of phase I to IV trials are now well defined.
However, the concept of translational research is not part of
this progression, simply because the need for translational
research - as part of therapy development - became evident
long after the concepts of phase I to III trials were defined.
For many anticancer therapies, such as targeted therapies,
identification of predictive markers for proper patient
selection is mandatory. Use of therapies that are directed at
well defined targets, such as trastuzumab and lapatinib, by
definition require measurement of specific molecular targets.
Although no proof for such a concept exists at present, we
can envision that the efficacy of other therapies - such as anti-
angiogenic treatment - may partly depend on molecular
markers such as vascular growth receptors [1].
Considering chemotherapy in general, we lack key
information about the mechanisms of drug resistance in vivo
[2]. Yet, the clinical observation of lack of cross-resistance
between different compounds such as taxanes and
anthracyclines [3] indicates that different mechanisms are
involved. Hence, identification of these mechanisms through
predictive testing may help to define the optimal therapy in
the individual patient. Turning our attention to endocrine
therapy, substantial therapeutic opportunities may result from
uncovering the mechanisms of acquired resistance among
receptor-positive tumours. Over the past decade we have
witnessed a dramatic increase in our fundamental biological
knowledge, as well as significant improvements in analytical
methods. Thus, the potential for improved predictive testing
has never been better. This being so, we must examine how
translational research can best be fitted into our general
clinical trial programmes.
Phase I studies
The aim of phase I studies is to explore drug toxicity.
Traditionally, such studies may involve about 12 to 20
patients who are treated with the drug under investigation at
escalating doses. This may be achieved either through dose
escalation in the same individuals or by increasing doses
between patient cohorts, for instance by using a Fibonacci
approach [4]. Often, such studies involve a pharmacokinetic
component, in which pharmacokinetic parameters such as
plasma half-life and drug clearance rate are assessed. For
many drugs the 95% confidence intervals for throughput
levels may span an interval in the order of about 1:4, but for
others (for example, medroxyprogesterone acetate adminis-
tered to breast cancer patients at high doses [500 to
1,000 mg] orally) throughput level 95% confidence intervals
may span an order of 1:10 [5]. This is probably due to inter-
individual variations in absorption as well as metabolism.
Such variations may have clinical implications for therapeutic
efficacy, questioning the need for routine plasma drug level
assessment [5].
Of most concern with respect to variations in metabolism is
atypical metabolism in some patients. The issue of poly-
morphic metabolism of tamoxifen related to therapy efficacy is
briefly commented upon in relation to phase III trials here and
in detail in another paper in this supplemental issue. Of
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importance to toxicity is the fact that some patients, because
of allelic polymorphisms, may suffer from parent drug or
metabolite accumulation, generating toxic side effects. Serious
problems in general are associated with homozygosity for a
poor metabolizing (or ‘PM’) allele. A classical example is that of
the antihypertensive agent debrisoquine; some patients experi-
ence hypotension together with high plasma levels of
unmetabolized drug in concert with low excretion of the major
4-hydroxylated metabolite in the urine [6]. In 1980, Evans and
coworkers [7] reported that 8% to 9% of UK Caucasians
inherit PM status for the antihypertensive agent debrisoquine in
a recessive manner. Another example is that of the oral anti-
diabetic tolbutamide. This compound is mainly metabolized
through cytochrome P450 (CYP)2C, which is also the
metabolic pathway for other important compounds, including
the active S-enantiomer of warfarin [8]. Among Caucasians, the
incidence of the PM *3 allele is about 6%. About 0.3% of the
population are poor metabolizers of these compounds because
of homozygosity for this allele, which may cause serious side
effects during therapy despite normal drug dosing. Notably, for
some CYPs, such as CYP2C19, the incidence of PM alleles
may vary between ethnic groups [8], supporting the need to
determine drug metabolism in different populations.
Although novel endocrine agents recently incorporated into
clinical practice have been associated with low toxicity, we
should not automatically infer that this will always be the case.
The first-generation aromatase inhibitor aminoglutethimide
exhibited significant toxicity, resulting in neurological side
effects and, in some cases, bone marrow toxicity [9]. Although
the pharmacokinetics of the compound were duly explored
[10], whether side effects such as drowsiness could be related
to variation in drug metabolism was never properly examined.
In summary, atypical metabolism caused by gene poly-
morphisms can be difficult to detect because of the low
incidence of many PM alleles, but side effects that may be
related to individual overdosing should provoke pharmaco-
genetic investigations to identify potential PM alleles that can
cause toxic effects in some patients.
Phase II studies
There are three main reasons why phase II studies represent a
key scenario in translational research. First, for many drugs,
identification of predictive markers is critical to deciding
whether the compound should move forward into a phase III
study. Second, because a limited number of patients is
enrolled in phase II protocols, dose selection for phase III
studies based on differences in responsiveness to different
drug doses in phase II trials may be suboptimal. Thus,
translational research with identification of suitable biomarkers
may add important information to the decision process. Third,
phase II studies conducted in dedicated centres may offer a
unique opportunity to collect tissue samples and conduct
molecular biological analyses aimed at identifying mechanisms
regulating drug sensitivity and resistance.
Helpful examples when considering the first issue include
targeted therapies such as endocrine treatment in general
and use of trastuzumab. None of these therapies achieved
their current clinical status without identification of target
proteins as predictive markers. For novel compounds, a
response rate of, say, 20% in general may not favour further
development. In addition to patient welfare, health authorities
currently mandate consideration of issues such as cost/utility
before they will approve therapies, be they ‘low cost’ [11] or
‘high cost’ [12]. Thus, eliminating, say, 50% of patients
predicted upfront to be nonresponders from inclusion in a
phase II trial may increase the response rate among
remaining patients from 20% to 40%. This is an outcome that
may potentially be critical in determining whether a
compound should advance into phase III studies.
Second, a critical part of phase II studies is proper dose
selection for further processing into phase III studies. For
instance, the efficacy of aromatase inhibitors may be deter-
mined though direct in vivo assessment of the key end-point,
aromatase inhibition, with use of radiolabelled steroid injec-
tions [13-15]. Applying this technique, we found anastrozole
1 mg/day to be as effective at inhibiting in vivo aromatization
and plasma oestrogen suppression as 10 mg/day [16]. In
contrast, when the selective oestrogen receptor (ER)
modulator droloxifene was compared with tamoxifen in an
international phase III study [17], a drug dose of 40 mg was
selected. The reason for this was that clinical results from a
phase II study [18] had revealed that droloxifene at
40 mg/day and 100 mg/day yielded similar response rates.
The phase III study reported that droloxifene 40 mg/day and
tamoxifen 20 mg/day yielded similar response rates in
postmenopausal women. In contrast, droloxifene was found
inferior in premenopausal women. This finding actually leads
one to question whether droloxifene was administered at a
suboptimal dose. This hypothesis is indirectly supported by
the finding that droloxifene 100 mg/day causes alterations in
plasma levels of sex hormone binding globulin, insulin-like
growth factor I and its major binding proteins, resembling
what we see during treatment with tamoxifen, whereas
droloxifene 40 mg/day exhibited only moderate effects [19-
23]. In this case, dose selection based on biomarkers
probably had been superior to dose selection on the basis of
response rates.
Regarding the third aim of phase II studies, we must
discriminate between biological end-points in phase II and
phase III studies. As outlined below, translational research in
phase III studies should aim to confirm predictive factors that
may be suitable for routine application. In contrast, in phase II
studies our biological research aims are much wider, namely
to identify the biological mechanisms underlying the observa-
tions recorded. Although in recent years pharmaceutical
companies have tended to try to get drugs through phase II
into phase III trials as quickly as possible, spending some
additional time on phase II studies and recruiting patientsPage 3 of 5
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suitable for translational research may be rewarding. Although
not every patient harbouring breast cancer metastases has
deposits that are suitable for a biopsy, lesions located in the
liver or locoregionally are, in general, suitable for Tru-Cut
tissue collection, and thus for snap-frozen tissue biobanking.
Predicting responsiveness to endocrine therapy or
trastuzumab, expression of the ER or amplification of the
human epidermal growth factor receptor (HER)-2 proto-
oncogene are good predictive factors. However, not every
patient with an ER-positive tumour responds to endocrine
manipulation, and not every patient exhibiting HER-2 amplifi-
cation benefits from targeted therapy with, for example,
trastuzumab. Most likely, there is no single mechanism of
growth factor inactivation; apart from simple over-expression
or under-expression of a protein product, we may be dealing
with proteins that are modified by single base non-sense or
mis-sense mutations, truncations or deletions [2]. Although
chemo-resistance has been linked to mutations in particular
genes that execute apoptosis or DNA repair, there is
emerging evidence that we need to focus on gene ‘pathways’
and not single gene products if we are to understand these
functions [24]. Furthermore, although non-sense mutations
eliminate the function of a gene product, the biological effect
of a mis-sense mutation (or a polymorphism) may be difficult
to predict upfront. For example, considering the key gene
TP53, whose protein product p53 is involved in growth arrest
as well as apoptosis and DNA repair, some mis-sense single
base substitutions (affecting DNA binding) may be
deleterious whereas other mutations appear to generate
normal functioning protein [25]. Finally, because various
drugs, including anthracyclines and taxanes, exhibit lack of
cross-resistance, clearly the mechanism of resistance must
differ. Thus, to explore drug resistance the mechanisms of
chemo-resistance should be explored in relation to drug
monotherapy whenever possible [26].
This approach may be illustrated with some examples.
Previously, we discovered mutations in TP53 to be
associated with resistance to anthracycline therapy in breast
cancer [25]. Looking for mutations in other genes that are
involved in the same pathway to account for resistance in
tumours harbouring wild-type TP53, we were able to exclude
mutations as well as polymorphisms that affect the p53
downstream target p21 [27,28]. In a recent phase II study in
which patients with primary, locally advanced breast cancers
were randomly assigned to epirubicin or taxol monotherapy
(Figure 1), we discovered non-sense mutations in the CHEK2
gene (which encodes the chk2 protein), one of the genes
acting upstream of p53 [29], to predict resistance to
epirubicin, similar to our observation regarding TP53 muta-
tions. In the same study, we excluded mutations in another
p53 activator, namely p19 (Figure 2). These discoveries
confirmed the importance of CHEK2  activating  TP53 in
response to DNA damage in vivo and provide information key
to our understanding of the apoptotic response in breast
cancer. However, with a minority of epirubicin-resistant
patients harbouring CHEK2 mutations, there is not yet any
clinical rationale for recommending CHEK2 gene sequencing
as a routine test in breast cancer patients. On the other hand,
if we are able to confirm that most patients exhibiting anthra-
cycline resistance harbour disturbances in the p53 ‘pathway’,
then much effort should be channelled toward developing a
predictive marker to identify general defects in this pathway.
Phase III studies
Predictive factors may serve two ultimate goals with respect
to phase III trials. In a similar manner to phase II studies, they
are needed to select the proper patient population for trial
enrolment. Second, they may identify subgroups of patients
who may benefit from one therapy as opposed to another.
Regarding the selection of patient populations for inclusion in
phase III trials, we may often benefit from the findings of
previous studies conducted to identify predictive markers.
Thus, the general opinion is that only patients harbouring ER
and/or progesterone receptor positive tumours are eligible for
trials evaluating endocrine agents. Similarly, HER-2 over-
expression and/or amplification is considered a requirement
for anti-HER-2 strategies to work.
Considering the second issue, the finding of a lack of cross-
resistance between cytotoxic compounds such as the anthra-
cyclines and taxanes supports the view that different
mechanisms of resistance are involved. Thus, a better under-
standing of such mechanisms may allow proper selection of
patients for each particular therapy. The question becomes
not whether the one drug may be superior for breast cancer
Available online http://breast-cancer-research.com/content/10/S4/S22
Figure 1
Example of a phase II study aiming at identifying mechanisms of drug
resistance. Presented is an example of a phase II study designed with
the primary aim of exploring mechanisms of resistance to epirubicin and
paclitaxel; each drug was administered as a monotherapy regimen [33].therapy in general, but rather which patients may benefit from
which treatment option, and how should we identify them?
A second example relates to pharmacogenomics. The CYP2D6
enzyme (responsible for converting tamoxifen into its active
metabolite 4-hydroxy-n-desmethyltamoxifen [endoxifen]) has a
polymorphic allele *4, which is associated with low enzymatic
activity. 4-Hydroxy-n-desmethyltamoxifen was initially described
by Lien and colleagues [30] in 1989. According to Goetz and
coworkers [31], who were first to describe the *4 allele,
about 20% of people exhibit heterogeneity for this variant,
whereas about 7% were found to be homozygous. Impor-
tantly, they revealed that patients homozygous for the *4 allele
had an inferior outcome compared with other patients
receiving tamoxifen treatment. Whether expression of the *4
allele predicts a poor outcome has been examined in several
recent reports, and whether it should be implemented for
clinical testing to select patients for tamoxifen therapy
remains an issue of debate [32]. Nevertheless, it illustrates an
important principle - pharmacogenetics may be an important
factor in selecting appropriate candidates for certain
treatments in the future.
Phase IV studies
Phase IV studies include various kinds of research conducted
after completion of the phase III studies that are pivotal for
registration. Whether the treatments are used for metastatic
disease or in the neoadjuvant (primary) setting, these studies
may offer a suitable opportunity for translational research,
with aims similar to those in phase II studies.
Conclusion
The extended need for translational research does not
change the planning of phase I to III and even phase IV
studies. However, the need for translational studies should be
emphasized. Translational research should not be considered
a ‘secondary aim’, proceeding in parallel with clinical studies
in general. Rather, we should regard translational research as
an integrated part of drug development during each phase of
the programme.
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